March 7, 2014

Announcements

Yale Cancer Center Members Present at AACR Annual Meeting
I am thrilled to see that Yale Cancer Center and Smilow Cancer Hospital will have great representation at the annual American Association for Cancer Research meeting in San Diego, CA April 5-9. Please review the schedule of presentations from Yale below when making your travel and agenda plans and be sure to support your colleagues while in attendance at the meeting.

Saturday, April 5

Methods Workshop
8:00 AM - 10:00AM
Location: Room 30A-C, San Diego Convention Center
Presentation Title: Next Generation Sequencing: From Bench to Bedside
Author Block: Lajos Pusztai, Tingting Jian

Location: Room 30A-C, San Diego Convention Center
Presentation Title: Bioinformatics analysis pipeline for exome sequencing data
Presentation Time: 8:20 AM - 8:40 AM
Author Block: Christos Hatzis

Location: Room 30A-C, San Diego Convention Center
Presentation Title: Information in non-coding DNA
Presentation Time: 9:20 AM - 9:40 AM
Author Block: Ekta Khurana

Educational Session
8:00 AM - 10:00 AM
Location: Room 33, San Diego Convention Center
Presentation Title: Beyond Ipilimumab and PD1/PD-L1 Pathway Blockade: Next Generation of Immunomodulatory Antibodies
Author Block: Mario Sznol

Educational Session
10:15 AM - 12:15PM
Location: Room 6CF, San Diego Convention Center
Presentation Title: Novel Approaches to Re-Awakening the
Immune System
Author Block: Lieping Chen

Educational Session
1:00 PM - 3 PM
Location: Room 25A-C, San Diego Convention Center
Presentation Title: Unraveling Therapeutic Resistance in Mouse Models of Human Cancer
Author Block: Katerina Politi

Educational Session
3:15 PM - 5:15 PM
Location: Room 31A-C, San Diego Convention Center
Presentation Title: Outside the Coding Genome: Non-Coding RNAs in the Oncogene and Tumor Suppressor Network
Author Block: Frank Slack

Sunday, April 6

Minisymposium
3:15 PM - 5:15 PM
Location: Room 31, San Diego Convention Center
Abstract Number: 974
Presentation Title: Targeting the tumor microenvironment with antimiRs that exploit oncomiR addiction in lymphoma
Presentation Time: 3:20 PM - 3:35 PM
Author Block: Christopher J. Cheng, Don M. Engelman, Mark Saltzman, Frank J. Slack

Location: Room 31, San Diego Convention Center
Abstract Number: 977
Presentation Title: Characterizing the regulation and function of miR-155 in hypoxia biology
Presentation Time: 4:05 PM - 4:20 PM
Author Block: Peter M. Glazer

Location: Room 5, San Diego Convention Center
Abstract Number: 985
Presentation Title: The mutational landscape of LN metastasis and recurrence in HNSCC
Presentation Time: 4:05 PM - 4:20 PM
Author Block: Gerald Goh, Roy S. Herbst, Richard P. Lifton

Location: Room 5, San Diego Convention Center
Abstract Number: 986
Presentation Title: Unraveling breast cancer progression through geographical and temporal sequencing
Presentation Time: 4:20 PM - 4:35 PM
Author Block: Lajos Pusztai

Location: Room 11, San Diego Convention Center
Abstract Number: 933
Presentation Title: Copy number changes are associated with BRAF and NRAS mutations and response to treatment
with carboplatin, paclitaxel and sorafenib

Presentation Time: 3:20 PM - 3:35 PM
Author Block: David L. Rimm, Harriet M. Kluger

Location: Room 6CF, San Diego Convention Center
Abstract Number: 961
Presentation Title: 6-phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumor growth by inhibiting LKB1-AMPK signaling
Presentation Time: 3:20 PM - 3:35 PM
Author Block: Titus Boggon

Poster Session
1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 3
Abstract Number: 59
Presentation Title: PDK1 in melanoma development and metastasis
Poster Board Number: 2
Author Block: Rossitza Lazova, Harriet Kluger, Marcus Bosenberg

Location: Hall A-E, Poster Section 28
Abstract Number: 654
Presentation Title: Targeting K-ras mutant cancer cells with a lupus anti-guanosine antibody
Poster Board Number: 11
Author Block: Melissa R. Young, Philip W. Noble, James E. Hansen

Location: Hall A-E, Poster Section 12
Abstract Number: 292
Presentation Title: Aberrant methylation of miR-34b as a potential mechanism for increased shiftwork-mediated breast cancer susceptibility
Poster Board Number: 9
Author Block: Daniel I. Jacobs1, Alan Fu, Yong Zhu

Location: Hall A-E, Poster Section 5
Abstract Number: 129
Presentation Title: AIP1 suppresses tumor metastasis by regulating tumor microenvironment and metastatic niche
Poster Board Number: 14
Author Block: Wang Min

Location: Hall A-E, Poster Section 37
Abstract Number: 920
Presentation Title: Secreted frizzled related protein 1 (SFRP1) as a potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC)
Poster Board Number: 25
Author Block: Lajos Pusztai

Location: Hall A-E, Poster Section 29
Abstract Number: 678

w/ BRCA-mutated adv.
#ovariancancer following 1st line chemo.

@nytimeswell Watch @AneesChagpar discuss "addressing the racial and ethnic disparities in #breastcancer."

Join Yale Cancer Center on Facebook

LATEST POSTS:

Having worked at Yale-New Haven Hospital since 1982 as an RN, Judy has cared for hundreds of cancer patients. That is why she quickly consulted a doctor after feeling a lump in her neck while taking a phone call at her desk. When the biopsy came back, it was clear that Judy had thyroid cancer.

Yale Cancer Center is committed to delivering on personalized care to each of our patients.

As explained in this video by Anees Chagpar, MD, and Katerina Politi, PhD, therapies delivered at Smilow Cancer Hospital at Yale-New Haven are targeted for each patient based on genetics and biology, and informed by research conducted by scientists at Yale Cancer Center.
**Presentation Title:** The Ets factor ETV5 regulates E2F target genes and mediates drug resistance
**Poster Board Number:** 5
**Author Block:** Danielle Greenberg

**Monday, April 7**

**Major Symposium**
1:00 PM - 3:00PM  
*Location:* Ballroom 20A-C, San Diego Convention Center  
**Presentation Title:** The rapidly evolving role of PD-1 pathway inhibition in other tumor types  
**Presentation Time:** 2:25 PM - 2:45 PM  
**Author Block:** Mario Sznol

**Current Concepts in Organ Site Research**  
1:00 PM - 3:00PM  
*Location:* Room 31A-C, San Diego Convention Center  
**Presentation Title:** Intro, molecular profiling and focus on EGFR mutated lung cancer  
**Presentation Time:** 1:00 PM - 1:20 PM  
**Author Block:** Thomas J. Lynch, Jr.

**Science Policy Session**  
10:30 AM - 12:30 PM  
*Location:* Room 1, San Diego Convention Center  
**Presentation Title:** Fostering evidence-based tobacco control: AACR research and policy initiatives  
**Author Block:** Roy S. Herbst

**Poster Session**  
8:00 AM - 12:00 PM  
*Location:* Hall A-E, Poster Section 19  
**Abstract Number:** 1468  
**Presentation Title:** The KRAS-variant, a miRNA disrupting inherited mutation in the 3'UTR of KRAS, causes EMT and unique cell biology  
**Poster Board Number:** 26  
**Author Block:** Joanne B. Weidhaas, David Salzman, Michelle Dookwah, Sunitha Nallur, Elcie Chan, Trupti Paranjape

**Location:** Hall A-E, Poster Section 33  
**Abstract Number:** 1792  
**Presentation Title:** Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer  
**Poster Board Number:** 5  
**Author Block:** Casey G. Langdon, Mathew A. Held, James T. Platt, Marcus W. Bosenberg, David F. Stern

---

**March is Colorectal Cancer Awareness Month.** Remind your loved ones who are at high risk or over age 50 to schedule their screening. 1 in 3 adults age 50-75 are not up-to-date with recommended colorectal cancer screening, but over 60% of deaths from colorectal cancer could be avoided with screening. SHARE this post and educate your friends.

**Events**

**March 7; 12:00 PM**  
YCC Research in Progress Meeting  
NP4-101A  
QOPI (Quality Oncology Practice Initiative) For Fellows - and Beyond  
Katherine Harvey, MD, MPH

**March 8; 8:30 AM**  
Discovery to Cure Event: A Day of Discovery  
Park Street Auditorium  
Exciting Developments in Research, Treatment Advances, & Quality of Life Initiatives. Clock-cancer connection: from epidemiology to pharmacology

**March 9; 6:00 PM**  
Yale Cancer Center Answers  
WNPR New Treatments for Cancer  
Lieping Chen, MD, PhD
Tea Polyphenols suppress non-small cell lung cancer angiogenesis and growth by regulating VEGF, NF-kB and MMPs expression

Abstract Number: 1015
Presentation Title: Tea Polyphenols suppress non-small cell lung cancer angiogenesis and growth by regulating VEGF, NF-kB and MMPs expression
Poster Board Number: 14
Author Block: Elizabeth Gullen, Yung-chi Cheng

sHER3 inhibits the proliferation and migration of melanoma-derived cells in a tenasin-dependent manner

Abstract Number: 1164
Presentation Title: sHER3 inhibits the proliferation and migration of melanoma-derived cells in a tenasin-dependent manner
Poster Board Number: 13
Author Block: Chunlin Cai

Identification and biological characterization of a novel class of small molecules to inhibit c-myc transcription

Abstract Number: 1629
Presentation Title: Identification and biological characterization of a novel class of small molecules to inhibit c-myc transcription
Poster Board Number: 12
Author Block: Peter Gareiss

Ovulatory wound: the site of origin for ovarian serous carcinoma

Abstract Number: 1974
Presentation Title: Ovulatory wound: the site of origin for ovarian serous carcinoma
Poster Board Number: 13
Author Block: Yang Yang-Hartwich, Marta Gurrea, Natalia Sumi, Jennie Holmberg, Vinicius Craveiro, Ayesha Alvero, Gil Mor

Study of Malformin C, a fungal cyclic pentapeptide, as an anti-cancer drug

Abstract Number: 2705
Presentation Title: Study of Malformin C, a fungal cyclic pentapeptide, as an anti-cancer drug
Poster Board Number: 6
Author Block: Caroline Zeiss, Amanda Beck

Axl overexpression drives migration and invasion in colon cancer

Abstract Number: 1991
Presentation Title: Axl overexpression drives migration and invasion in colon cancer
Poster Board Number: 3
Author Block: Lidia Bosurgi, Nicola Gagliani, Leonel Joannas, Carla V. Rothlin

RNF5 mediates ER stress-induced degradation of SLC1A5 in breast cancer

Abstract Number: 2440
Presentation Title: RNF5 mediates ER stress-induced degradation of SLC1A5 in breast cancer
Poster Board Number: 11
Author Block: Sihem Khelifa, David L. Rimm, Yuval Kluger
Location: Hall A-E, Poster Section 12
Abstract Number: 2167
Presentation Title: Infertility and risk of incident endometrial carcinoma: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium
Poster Board Number: 12
Author Block: Lingeng Lu, Harvey Risch

Location: Hall A-E, Poster Section 37
Abstract Number: 2840
Presentation Title: Evaluation of HER-2 RNA and protein levels in a large cohort of breast cancer specimens to support development of a diagnostic immunofluorescence assay quantified by AQUA® Technology
Poster Board Number: 21
Author Block: David Rimm

Location: Hall A-E, Poster Section 11
Abstract Number: 2146
Presentation Title: The chemo-preventive effect of ER-β agonist on DMBA induced breast cancers
Poster Board Number: 21
Author Block: Young J. Choi

Location: Hall A-E, Poster Section 13
Abstract Number: 2214
Presentation Title: Genome-wide gene-diabetes and gene-obesity interaction scan in the pancreatic cancer case control consortium
Poster Board Number: 29
Author Block: Harvey A. Risch

Location: Hall A-E, Poster Section 35
Abstract Number: 2781
Presentation Title: Elimination of PanIn2/3 in a GEMM for pancreatic cancer with disrupted p16 and activated Kras
Poster Board Number: 22
Author Block: Daniel P. Petrylak

Tuesday, April 8

Regulatory Science and Policy Session
10:30 AM - 12:30PM
Location: Room 30A-C, San Diego Convention Center
Presentation Title: The Lung Master Protocol as an example of abiomarker-driven, multidrug, multi-arm Phase 2/3 registration trial
Author Block: Roy S. Herbst

Current Concepts in Organ Site Research
1:00 PM - 3:00 PM
Location: Room 7, San Diego Convention Center
Presentation Title: The Genomics of Neuroendocrine Neoplasia: From Gnosis to Sunesis
Presentation Time: 2:15 PM - 2:35 PM

Smilow, LL-412, Room E
M&M Conference
James Yu, MD
Learn More >>

March 14; 12:00 PM
YCC Prevention and Control Research Program Meeting
LEPH 216
The Demands of Breast Cancer Survivorship: Clinical Care and Translational Research
Jennifer R. Klemp, PhD, MPH, MA
Learn More >>

March 14; 12:00 PM
YCC Research in Progress Meeting
NP4-101A
TBA
Ami Jhaveri, MD and Carolyn Presley, MD
Learn More >>

March 14; 1:00 PM
YCC Molecular Virology Research Program
SHM I-116
Why the Epstein-Barr Virus Needs a Non-coding RNA to Persist
Nara Lee, PhD
Learn More >> (PDF)

March 16; 6:00 PM
Yale Cancer Center Answers WNPR Dermatopathology
Rossitza Lazova, MD
Learn More >>

March 18; 9:30 AM
Pathology Research in Progress Talks
TAC N-107
TBA
Deborah Ayeni and Mate Nagy
Learn More >>

March 18; 12:00 PM
Yale Cancer Center Grand Rounds
Park Street Auditorium
From Benchtop to Shelftop: Moving Therapy for Cancer from Discovery through to the Market
Peter Marks, MD, PhD
Learn More >>

March 20; 9:00 AM
Therapeutic Radiology Grand Rounds
Smilow, LL-412, Room E
Author Block: Irvin Modlin

Poster Session
8:00 AM - 12:00PM
Location: Hall A-E, Poster Section 4
Abstract Number: 3049
Presentation Title: Regulation of cancer cell stemness by delta-like 1 homolog (Drosophila) and prohibitins
Poster Board Number: 18
Author Block: Qun Lin, Asma Begum, Chenye Yu, Ming-Yeh Hu, Yuri Kim, Zhong Yun

Location: Hall A-E, Poster Section 18
Abstract Number: 3434
Presentation Title: Genomic exome DNA sequencing identifies top driver genetic alterations in head and neck cancer cell lines of different HPV status
Poster Board Number: 24
Author Block: Wendell G. Yarbrough

Location: Hall A-E, Poster Section 3
Abstract Number: 3012
Presentation Title: Converging effectors of airway lineage specification and metastasis in lung cancer
Poster Board Number: 4
Author Block: Don X. Nguyen

Location: Hall A-E, Poster Section 16
Abstract Number: 3362
Presentation Title: Tyr-phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate pyruvate dehydrogenase complex and promote the Warburg effect
Poster Board Number: 12
Author Block: Titus Boggon

Location: Hall A-E, Poster Section 38
Abstract Number: CT 313
Presentation Title: An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)
Poster Board Number: 13
Author Block: Hari Deshpande

Poster Session
1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 29
Abstract Number: 4498
Presentation Title: Afatinib, an irreversible ErbB family inhibitor, demonstrates activity against HER2 mutated cervical cancer in vitro
Poster Board Number: 8
Author Block: Salvatore Lopez, Emiliano Cocco, Bellone Stefania, Ileana Bortolomai, Elena Bonazzoli, Roberta Nicoletti, Carlton Schwab, Diana P. English, Alessandro D. Santin

Medical Student Presentation
Adriana Blakaj

March 21; 12:00 PM
YCC Research in Progress Meeting
NP4-101A
TBA
Jill Lacy, MD, Stacy Stein, MD, and Howard Hochster, MD

Closer to Free

Employment Opportunities

Success in any clinical research endeavor, but especially in cancer research, requires the most qualified, dedicated staff, committed to excellence and the mission of Yale Cancer Center. The combination of education, oncology research experience, and exceptional nursing skills is enormously difficult to find. Your participation, as knowledgeable colleagues, is invaluable at this time.

Should you know individuals with outstanding clinical research nursing experience, and who are ready to join our team, please direct resumes to Sandra Greer, Sr. Staffing and Career Development Representative or call (203) 432-5822. All referrals will be held in strictest confidence.

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette
**Abstract Number:** 4319

**Presentation Title:** Inability of putative ovarian cancer stem cells to engage OXPHOS confer 2-deoxyglucose-mediated prevention of in vivo recurrence

**Author Block:** Ayesha B. Alvero, Michele Montagna, Natalia J. Sumi, Won Duk Joo, Vinicius Craveiro, Emma Graham, Gil Mor

**Location:** Hall A-E, Poster Section 21

**Abstract Number:** 4220

**Presentation Title:** A cell-penetrating nucleolytic lupus autoantibody damages DNA and is toxic to BRCA2-deficient cancer cells

**Author Block:** Philip W. Noble, Melissa R. Young, James E. Hansen

**Location:** Hall A-E, Poster Section 16

**Abstract Number:** 4520

**Presentation Title:** Inhibition of melanoma growth by small molecules that attenuate PI3K/PDK1 signaling and promote ATF2 mitochondrial localization

**Author Block:** Marcus Bosenberg

**Location:** Hall A-E, Poster Section 30

**Abstract Number:** 4548

**Presentation Title:** The anti-proliferative activity of TAS-108 (a steroid anti-estrogen) is augmented by high ERβ levels in breast cancer cells

**Author Block:** Young J. Choi

**Location:** Hall A-E, Poster Section 31

---

**Wednesday, April 9**

**Major Symposium**

11:00 AM - 1:00 PM

**Location:** Room 5, San Diego Convention Center

**Presentation Title:** Novel DNA repair inhibitors for radiosensitization and cancer therapy

**Presentation Time:** 12:00 PM - 12:20 PM

**Author Block:** Peter M. Glazer

**Poster Session**

8:00 AM - 12:00 PM

**Location:** Hall A-E, Poster Section 5

**Abstract Number:** 4937

**Presentation Title:** Fluorescence imaging using Clostridium Perfringens Enterotoxin carboxi-terminal fragment (c-CPE) to target metastatic chemotherapy-resistant human ovarian cancer in xenograft mice

**Poster Board Number:** 17
Author Block: Casey G. Langdon, Mathew A. Held, James T. Platt, Marcus W. Bosenberg, David F. Stern

Location: Hall A-E, Poster Section 30
Abstract Number: 5441
Presentation Title: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models
Poster Board Number: 15

Location: Hall A-E, Poster Section 32
Abstract Number: 5476
Presentation Title: Simultaneous targeting of multiple cancer-related pathways in HPV-positive head and neck cancer with demethylating agents
Poster Board Number: 2
Author Block: Asel Biktasova, Mi Zou, Wendell G. Yarbrough, Natalia Issaeva

Location: Hall A-E, Poster Section 12
Abstract Number: 5039
Presentation Title: Physical activity is associated with improved quality of life in cancer survivors: A population-based analysis
Poster Board Number: 2
Author Block: Apoorva Tewari, Melinda Irwin, Anees Chagpar

Location: Hall A-E, Poster Section 13
Abstract Number: 5072
Presentation Title: Meta-analysis of genome-wide association studies identifies novel susceptibility loci for follicular lymphoma
Poster Board Number: 14
Author Block: Yawei Zhang

Location: Hall A-E, Poster Section 26
Abstract Number: 5348
Presentation Title: Impaired self-renewal and colitis susceptibility of colonic mucosa in mice lacking AKR1B8
Poster Board Number: 6
Author Block: Laxiang Wan

Notables

Alfred Bothwell, PhD, a member of the Cancer Immunology Program, has received an RO1 grant entitled “Regulatory T cell Control of Intestinal Tumorigenesis” from the National Cancer Institutes. Dr. Bothwell's research will look to give important
mechanistic insight into the specific inflammatory molecules that can compromise cells of the immune system.

**Dena Schulman-Green, PhD**, a member of the Cancer Prevention and Control Program, has been awarded an R21 grant to study "Integrating Palliative Care into Self-Management of Breast Cancer." Working with Dr. Anees Chagpar, Dr. Sangchoon Jeon, Dr. Jennifer Kapo, and Leslie Blatt, APRN, the purpose of the study is to test a psycho-educational intervention intended to improve patients' knowledge of palliative care and to facilitate its timely integration into self-management of their breast cancer.

The Connecticut Academy of Science and Engineering announced that six members of Yale Cancer Center were elected to membership on the basis of their distinguished contributions to science or engineering. The YCC members are **Ronald Breaker**, **Lynn Cooley**, **Daniel DiMaio**, **James Duncan**, **Theodore Holford**, **Stephanie O'Malley**, and **Patrick Sung**.

**Rhoda Arzoomanian, RN, MSM**, has been appointed as associate director of Yale Cancer Center and the Yale Center for Clinical Investigation (YCCI). A nationally recognized expert in cancer clinical research, clinical trials databases, and the management of an NCI-designated cancer center, Arzoomanian has over 25 years of clinical research experience. She joins Yale from the University of Wisconsin Carbone Comprehensive Cancer Center (UWCCC), where she has held the position of associate director of administration since 2010.

Arzoomanian's leadership role will encompass clinical research across the medical campus, including Yale Cancer Center. She will oversee clinical research regulatory units, developing results-oriented strategies for these areas, as well as testing and verifying compliance and good clinical practices. Her experience over the past 15 years working on three Cancer Center Support Grants at the UWCCC will be invaluable in her role at Yale, as will her ability to bring people from diverse backgrounds together.

**Stephanie Signore** will be joining us as the Operations Manager for Yale Cancer Center on March 31. In this role, she will oversee finance, administration, and business operations for the clinical sections of medical oncology, hematology, palliative care, and neuro-oncology. Stephanie joins us from the Department of Surgery where she has been since 2006 and where she is responsible for the financial administration of their clinical practices with oversight of an operating budget in excess of $84 million. Prior to joining Yale in 2000, she worked in corporate accounting and auditing in the private sector. She holds a BS in Business Administration from the University of Connecticut.
Research in the News

**Gene regulator critical for breast cancer metastasis to the lung is identified**

Yale Cancer Center researchers have identified a regulator of gene expression that is responsible for the progression of breast cancer and its metastasis to the lung. The study appears online in Cell Reports.

The Yale researchers analyzed gene expression datasets of human breast tumors, as well as those of cancer cells, and found that overexpression of the enzyme RBP2 is critical for breast cancer metastasis to the lung. Loss of RBP2, they also found, suppressed tumor formation in mouse models.

The authors say their evidence suggests that RBP2 regulates a critical epigenetic switch that sets the stage for tumor metastasis. They say the enzyme offers a novel target for development of therapies designed to inhibit tumor progression and metastasis.

[Read More >>]

---

Closer to Free

You've waited all winter, endured snowstorm after snowstorm and dug your car out countless times, but finally the day has come. We're happy to announce that registration for the 2014 Closer to Free Ride is now open! We will once again offer three incredible routes of 25 miles, 62.5 miles or 100 miles and, speaking of 100, 100% of the funds you raise will go directly to support research and care at Smilow Cancer Hospital and Yale Cancer Center.

September 6 might not feel like it's right around the corner but it is. And we hope that on that day you'll join more than a thousand others as we ride Closer to Free.

This is Your Ride.

[Learn More and Register Now >>]
Funding and Award Opportunities

Alex's Lemonade Stand Foundation
We are pleased to announce that grant guidelines and applications are now open for submission in the following categories:

Bridge Grants Cycle
This grant is designed to sustain research projects falling between the end of funding by the National Institutes of Health (NIH) R or P Award and the beginning of a competitively renewed NIH Award. Renewal applications which scored less than or equal to the 35th percentile but were not funded will be eligible for Bridge Grants. Applicants must have a plan to resubmit for NIH funding. This is a one year award of $100,000 in total costs.

**Application Deadline:** April 10, 2014

Springboard Grants Cycle
This grant supports new National Institutes of Health (NIH) R01 or P01 research applications which were scored less than or equal to the 25th percentile but were not funded. Applicants must have a plan to resubmit for NIH funding. This is a one year award of $100,000 in total costs.

**Application Deadline:** April 10, 2014

'A' Awards
NEW in 2014, the award amount has increased to $150,000 per year for three years! Designed for early career scientists with an original project who can demonstrate outstanding mentorship and have a strong future commitment to pediatric cancer investigation. This award totals $450,000 over three years and is open to MD, MD/PhD and PhD candidates.

**Application Deadline:** May 23, 2014

Reach Awards
Our Reach Awards are designed to move hypothesis-driven research toward the clinic. The goal of this award is to support selected "late translational" studies needed to ultimately initiate a clinical trial. A successful application will identify an unmet clinical need relevant to the care of pediatric cancer patients and describe how the proposed project will allow for the pre-clinical research to be translated to the clinic while keeping broader clinical testing and implementation in view. Maximum of $250,000 in total costs awarded over two years.

**Application Deadline:** May 30, 2014

Learn More >>

Breast Cancer Alliance Exceptional Project Grants

- For clinical doctors and research scientists whose primary focus is breast cancer.
- **Candidates are eligible at any stage of their careers.**
- The proposed research must be directly related to the field of breast cancer.
- Areas of relevant research may include, but are not limited to: diagnosis, etiology, immunology, genetics, therapies,
prevention, and clinical studies.

**Internal Deadline:** Monday, March 17, 2014
Learn More >> (PDF)

**Sontag Foundation Early Career Distinguished Scientist Award**
Career development award supporting early career scientists with inspiring, potential-laden brain cancer proposals. The foundation is highly interested in researchers that may bring new perspectives to bear on the complex questions related to brain cancer. Up to $600,000 over 4 years.

**Application Deadline:** March 20, 2014
Learn More >>

**New York Stem Cell Foundation Investigator Awards in Neuroscience or Stem Cell Research**
Early career innovator awards for investigators in Neuroscience or Stem Cell Research. The Neuroscience Award seeks proposals in the fundamental areas of developmental, cellular, cognitive and behavioral neuroscience, broadly interpreted. The Stem Cell Award seeks proposals that will advance the understanding and use of stem cells in the development of treatments for human disease. Award is $1.5 M over 5 years.

**Application Deadline:** March 17, 2014
Learn More >>

**Lung Cancer Research Foundation Grants**
Support research on innovate strategies for better treatments, screening, and prevention of all cancers of the lung. These awards are designed to provide critical seed support for cutting-edge scientific research on all lung cancers and will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes. Up to $50,000 for 1 year.

**Application Deadline:** June 16, 2014
Learn More >>

---

**Employee Profile:**
**Sherry Tutillo**

*The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being done here, and the dedication and values we possess.*

*To suggest someone to be profiled, please contact*
Emily Fenton.

When Sherry Tutillo started as Administrative Assistant for Head and Neck Surgery at Smilow over a year ago, she wasn't sure what to expect. But with the support of the nursing staff and Drs. Benjamin Judson and Wendell Yarbrough she has learned a lot in a short amount of time. She is responsible for the scheduling of patient appointments, and recently began attending clinic sessions in the 4th floor multispecialty clinic allowing her to meet with patients and begin scheduling and coordinating further appointments and care right then and there.

Sherry's main goal is to make things easy and convenient for the patients. Even if they choose not to schedule their surgery right away, they appreciate knowing who they can contact when needed. However, if they decide to schedule their surgery, Sherry can consolidate their appointments for them and make sure everything is done in one day, when possible. “I like to put myself in the patient's shoes, what if it was me, or a family member, how would I want them to be treated,” said Sherry. “When I sit down with a patient I want to make sure they are as comfortable as possible, and I try to be positive. I want them to leave here knowing what to expect, and not having to worry about when their next appointment is. It is all taken care of for them.”

Date of surgery, follow-up, pre-op and post-op are all scheduled through Sherry, and if any additional scans or tests are required, she makes sure those are done to avoid any surprises. Working with a patient's schedule, along with the physician's clinic hours, is a difficult, yet rewarding task, commented Sherry. "Many patients just don't expect us to work around their schedules as well. They are so thankful when their next appointment is earlier then they expected, and with no hassle."

Benjamin Judson, MD, Assistant Professor of Surgery (Otolaryngology), commented, "Sherry has become an integral part of the head and neck care team and consistently goes above and beyond for our patients."

Recent Publications

Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue
Aktas, Hongxia Sun, Hui Yao, Weiwei Shi, Rebekah Hubbard, Ya Zhang, Tingting Jiang, Sophia N. Ononye, Vikram B. Wali, Lajos Pusztai, W Fraser Symmans, Christos Hatzis. 
Molecular Oncology. 17 Feb 2014.
Read More >>

Association of Type of Renal Surgery and Access to Robotic
Technology for Kidney Cancer: Results From A Population-Based Cohort.

Specialty bias in treatment recommendations and quality of life among radiation on cologists and urologists for localize prostate cancer

The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease.

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer.

Fusion of bone marrow-derived cells with cancer cells: metastasis as a secondary disease incancer.

MEK targeting in N-RAS mutated metastatic melanoma.


Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, Booth CJ, Nguyen DX, Yan Q.
Read More >>

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base.
Read More >>

Integrative Analysis of Cancer Diagnosis Studies with Composite Penalization.
Liu J, Huang J, Ma S.
Read More >>

Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective.
Brose MS, Frenette CT, Keefe SM, Stein SM.
Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16.
Read More >>

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
Buza N, Roque DM, Santin AD.
Read More >>

SRF is required for neutrophil migration in response to inflammation.
Read More >>